Opna Bio, a clinical-stage biopharmaceutical company focused on the discovery and development of novel oncology therapeutics, announced today that the FDA has granted orphan drug designation (ODD) to ...

(NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmission of the Biologics License Application (BLA) for linvoseltamab for the treatment ...

Dana-Farber Cancer Institute researchers will present key research studies at the 2025 Tandem Meetings, the premier ...

The North Chicago drugmaker says it could pay Xilio Therapeutics more than $2.1 billion in a collaboration and ...

Welcome to the Adaptive Biotechnologies fourth-quarter and full-year 2024 financial results conference call. (Operator Instructions) Please be advised that today's conference is being recorded. I ...

The Scientific Review Committee (SRC) charter is to review the safety data from the patients treated in the Phase I portion ...

Medical review of Phase 1 cohorts demonstrated no safety issuesData to be presented at the 10th Annual Innate Killer Summit, March 3-5 BOCA RATON, Fla, Feb. 12, 2025 (GLOBE NEWSWIRE) -- INmune Bio ...